FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function

Phase 2

Terminated

Conditions: Laryngeal Neoplasms

Interventions: Radiation: IMRT Radiation

First Posted Date: 2015-12-17

Last Posted Date: 2021-03-09

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 2

Registration Number: NCT02633540

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Cutaneous T-cell Lymphoma (CTCL)

Interventions: Drug: Romidepsin
Drug: Brentuximab vedotin

First Posted Date: 2015-11-30

Last Posted Date: 2024-02-28

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 16

Registration Number: NCT02616965

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pennsylvania, Perelman Center, Philadelphia, Pennsylvania, United States

Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients

Phase 2

Completed

Conditions: Cancer of Prostate

Interventions: Drug: Observation and Bicalutamide
Drug: Metformin and Bicalutamide

First Posted Date: 2015-11-25

Last Posted Date: 2022-03-29

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 29

Registration Number: NCT02614859

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
National Cancer Institute, Bethesda, Maryland, United States

Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: interferon-gamma and nivolumab

First Posted Date: 2015-11-25

Last Posted Date: 2019-11-29

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 26

Registration Number: NCT02614456

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Phase 1

Completed

Conditions: Advanced Solid Tumors
Multiple Myeloma

Interventions: Drug: ONC-201

First Posted Date: 2015-11-20

Last Posted Date: 2021-06-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 33

Registration Number: NCT02609230

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Cervical Cancer Screening Intervention Among Korean American Women

Not Applicable

Completed

Conditions: Cervical Carcinoma

Interventions: Behavioral: Culturally appropriate intervention
Behavioral: General health education control

First Posted Date: 2015-11-03

Last Posted Date: 2021-01-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 744

Registration Number: NCT02594826

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

Phase 2

Terminated

Conditions: Sporadic Angiomyolipomas (AMLs)

Interventions: Drug: Everolimus

First Posted Date: 2015-09-03

Last Posted Date: 2022-12-15

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 20

Registration Number: NCT02539459

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 5 locations

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, T-Cell, Peripheral

Interventions: Drug: MK-3475
Drug: Copanlisib

First Posted Date: 2015-08-28

Last Posted Date: 2022-07-08

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 17

Registration Number: NCT02535247

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Perioperative Risk Study

Not Applicable

Active, not recruiting

Conditions: Primary Neoplasm
Surgery
Tumors
Secondary Neoplasm

Interventions: Other: Standard postoperative care
Other: Preoperative risk stratification
Other: Postoperative risk stratification
Other: Risk-based, escalating levels of care
Other: Risk-based, escalating levels of monitoring
Other: Risk-based, escalating levels of co-management

First Posted Date: 2015-05-28

Last Posted Date: 2024-03-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 1456

Registration Number: NCT02456389

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Biobehavioral Model of Diabetes Risk in Chinese Immigrants

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2015-05-20

Last Posted Date: 2021-06-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 650

Registration Number: NCT02449213

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy